Our Portfolio
ReST is focused on preventing PTSD consolidation as a primary indication with several other programs in development, focused on neurodegenerative diseases and neuropsychiatric disorders, based on its targeted & selective NMDAR channel inhibition platform.
About RST-01
RST-01 is a novel and proprietary chemical entity specifically targeting certain NMDA receptor subtypes involved in synaptic plasticity. It facilitates stress extinction and neuroprotection without triggering the adverse side effects classically encountered with less selective NMDA targeting drugs. RST-01 restores the memorization process when taken following a traumatic event. We are on track to submit to submit our IND Application in H2 2024
